SelectScience
Join Free
Accelerating Science
NewsClinical Diagnostics

Sequenta Launches ClonoSIGHT, First Sequencing-based Minimal Residual Disease Test for Leukemia and Lymphoma

14 Feb 2013

Product news

Sequenta, Inc. announced today the commercial launch of ClonoSIGHT™, the first sequencing-based test for minimal residual disease (MRD) for leukemia and lymphoma. The ClonoSIGHT MRD test has been shown to offer unprecedented sensitivity for the detection of residual cancer cells in marrow or blood. Test results are generated in seven days using Sequenta’s CLIA-certified laboratory and can be used to better measure a patient’s risk of post-treatment relapse and guide subsequent care.

“The launch of ClonoSIGHT marks an important step toward improved treatment paradigms in blood cancers which are driven by sensitive and specific measurements of residual disease,” said Tom Willis, Ph.D., Sequenta’s chief executive officer. “This product builds on more than two decades of clinical research into the value of MRD and brings the incredible power of next-generation sequencing to bear on the important problem of rare cancer cell detection.”

The ClonoSIGHT test uses Sequenta’s proprietary LymphoSIGHT™ platform, which works by sequencing unique DNA signatures that are present in immune cells to allow tracking of malignant sub-populations even when they are present at levels as low as one cell per million white blood cells. The sequencing-based readout provides quantitative results that can be directly interpreted by oncologists.

“The LymphoSIGHT technology has been validated in the past year in more than 10 clinical trials, two of which have already appeared in peer-reviewed journals, with others under review,” said Malek Faham, M.D., Ph.D., chief scientific officer at Sequenta. “These studies have demonstrated not only the technical improvements in sensitivity and specificity of the ClonoSIGHT test, but also the relevance of its performance for patient prognosis in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).”

These early studies have shown that the LymphoSIGHT method was able to detect residual disease in as many as 10 percent of children with ALL who were negative by flow cytometry. It also detected residual disease in significant numbers of MCL patients who were negative by PET scans and subsequently suffered fatal relapses. Larger studies, including prospective studies conducted by oncology cooperative groups, are currently underway to extend the validation of the test.

Tags

Gas ChromatographyGas chromatography (GC) is an analytical technique used to separate and quantitate mixtures of small and volatile compounds. Gas chromatographs or GC systems include components such as GC columns, detectors, pumps and autosamplers. Choose from packed or capillary GC columns, flame ionization (FID), photoionization (PID) electron capture detectors and selective or non-selective detectors. Find the best gas chromatographs in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.MicroplatesMicroplates are multi-well plates used to increase the throughput of biological investigations. The number of wells microplates contain can range from 6 to 3243 wells, with the 96-well format being the most commonly used. Microplates can come tailored for a range of applications including cell culture, PCR, filtration, storage, non-binding surface, protein crystallization, as well as pre-coated, deep well and normal Standard microplates. Additionally, options for microplate colors include clear , black, white or black with clear bottom and white with clear bottom for absorbance microplate reader applications. Find the best microplates for your lab in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.HematologyIn Haematology / Hematology, complete blood cell counts (or full blood counts) are obtained using automated blood count analyzers to enumerate blood cell types.  Hematology also encompasses haemostasis and coagulation, thrombophilia and hemophilia, plasma viscosity and ESR analysis, hemoglobinopathies, cell morphology and haematinic measurement.Clinical ChemistryBiochemistry (or clinical chemistry) involves the analysis of bodily fluids using chemical tests. Techniques used include HPLC, chromatography, spectroscopy, mass spectrometry, immunochemical, electrophoresis, turbidometric / spectrophotometric assay, MRI and ISE analysis. Tests are often carried out on plasma or serum but urine (urinalysis) and fecal specimens are also processed.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.Cancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.LeukemiaIn Vitro DiagnosticsIn vitro diagnostics (IVD) involve testing samples outside the body, typically in a laboratory, to diagnose diseases or conditions. IVD technologies include blood tests, molecular assays, and other bodily fluid tests, enabling accurate diagnosis and monitoring of diseases. These tests are essential for guiding treatment decisions in clinical settings. Browse our peer-reviewed product directory to find the best IVD solutions; compare products, check reviews, and get pricing directly from manufacturers.

Related articles

Sequenta Launches ClonoSIGHT, First Sequencing-based Minimal Residual Disease Test for Leukemia and Lymphoma